ArticleTranslational gastroenterology and hepatology2026
Dual-input dual-compartmental uptake and efflux model based on Gd-EOB-DTPA-enhanced MRI for simultaneously assessing liver function and fibrosis.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver function assessment and fibrosis staging are crucial for monitoring therapeutic efficacy and guiding surgical management in patients with chronic liver disease. This study aimed to determine whether pharmacokinetic parameters derived from dual-input dual-compartmental uptake and efflux model based on Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) could simultaneously assess liver function and fibrosis. Methods: Thirty rats were enrolled in this study. Thioacetamide (TAA) was administered for 2, 4, 6, and 8 weeks to induce liver fibrosis. The METAVIR system (F0-F4) was used to stage fibrosis. Pharmacokinetic modeling was performed in a voxel-wise manner to generate parametric maps, from which mean values were extracted using liver regions of interest (ROIs). Pharmacokinetic parameters, including plasma flow rate ( Results: There were 6, 11, and 13 rats designated into the control (F0), early fibrosis (F1-2), and advanced fibrosis groups (F3-4), respectively. With the progression of liver fibrosis, Conclusions: The pharmacokinetic parameters derived from dual-input dual-compartmental uptake and efflux model, especially for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.